These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 19205734)

  • 21. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
    Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
    Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A.
    Nagano A; Ohno T; Shimizu K; Hara A; Yamamoto T; Kawai G; Saitou M; Takigami I; Matsuhashi A; Yamada K; Takei Y
    Int J Cancer; 2010 Jun; 126(12):2790-8. PubMed ID: 19642105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.
    Huang HJ; Angelo LS; Rodon J; Sun M; Kuenkele KP; Parsons HA; Trent JC; Kurzrock R
    PLoS One; 2011; 6(10):e26060. PubMed ID: 22022506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.
    Mutz CN; Schwentner R; Aryee DNT; Bouchard EDJ; Mejia EM; Hatch GM; Kauer MO; Katschnig AM; Ban J; Garten A; Alonso J; Banerji V; Kovar H
    Oncotarget; 2017 Apr; 8(15):24679-24693. PubMed ID: 28160567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma.
    Jess J; Sorensen KM; Boguslawski EA; Stout MC; Madaj ZB; Caiello BP; Pomaville M; Wilson ER; Kinn-Gurzo SS; Parker CC; Veluvolu SM; Brysgel TV; Kaufman R; Kitchen-Goosen SM; Gedminas JM; Grohar PJ
    Clin Cancer Res; 2024 Aug; 30(16):3533-3548. PubMed ID: 38506712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma.
    Mateo-Lozano S; Gokhale PC; Soldatenkov VA; Dritschilo A; Tirado OM; Notario V
    Clin Cancer Res; 2006 Nov; 12(22):6781-90. PubMed ID: 17121899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
    Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
    Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ewing sarcoma EWS protein regulates midzone formation by recruiting Aurora B kinase to the midzone.
    Park H; Turkalo TK; Nelson K; Folmsbee SS; Robb C; Roper B; Azuma M
    Cell Cycle; 2014; 13(15):2391-9. PubMed ID: 25483190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
    Ripple MO; Kalmadi S; Eastman A
    Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B.
    Winter GE; Rix U; Lissat A; Stukalov A; Müllner MK; Bennett KL; Colinge J; Nijman SM; Kubicek S; Kovar H; Kontny U; Superti-Furga G
    Mol Cancer Ther; 2011 Oct; 10(10):1846-56. PubMed ID: 21768330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo.
    Miyoshi S; Hamada H; Hamaguchi N; Kato A; Katayama H; Irifune K; Ito R; Miyazaki T; Okura T; Higaki J
    Int J Oncol; 2012 Aug; 41(2):449-56. PubMed ID: 22580933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
    Nonaka M; Itamochi H; Kawaguchi W; Kudoh A; Sato S; Uegaki K; Naniwa J; Sato S; Shimada M; Oishi T; Terakawa N; Kigawa J; Harada T
    Int J Gynecol Cancer; 2012 Jul; 22(6):922-9. PubMed ID: 22672985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genotoxic stress inhibits Ewing sarcoma cell growth by modulating alternative pre-mRNA processing of the RNA helicase DHX9.
    Fidaleo M; Svetoni F; Volpe E; Miñana B; Caporossi D; Paronetto MP
    Oncotarget; 2015 Oct; 6(31):31740-57. PubMed ID: 26450900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy.
    Romo-Morales A; Aladowicz E; Blagg J; Gatz SA; Shipley JM
    Pediatr Blood Cancer; 2019 Sep; 66(9):e27888. PubMed ID: 31207107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G
    Zöllner SK; Selvanathan SP; Graham GT; Commins RMT; Hong SH; Moseley E; Parks S; Haladyna JN; Erkizan HV; Dirksen U; Hogarty MD; Üren A; Toretsky JA
    Sci Signal; 2017 Oct; 10(499):. PubMed ID: 28974650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors.
    Castillero-Trejo Y; Eliazer S; Xiang L; Richardson JA; Ilaria RL
    Cancer Res; 2005 Oct; 65(19):8698-705. PubMed ID: 16204038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oligonucleotides targeted against a junction oncogene are made efficient by nanotechnologies.
    Maksimenko A; Malvy C; Lambert G; Bertrand JR; Fattal E; Maccario J; Couvreur P
    Pharm Res; 2003 Oct; 20(10):1565-7. PubMed ID: 14620508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors.
    Toretsky JA; Thakar M; Eskenazi AE; Frantz CN
    Cancer Res; 1999 Nov; 59(22):5745-50. PubMed ID: 10582694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Focal adhesion kinase confers pro-migratory and antiapoptotic properties and is a potential therapeutic target in Ewing sarcoma.
    Steinestel K; Trautmann M; Jansen EP; Dirksen U; Rehkämper J; Mikesch JH; Gerke JS; Orth MF; Sannino G; Arteaga MF; Rossig C; Wardelmann E; Grünewald TGP; Hartmann W
    Mol Oncol; 2020 Feb; 14(2):248-260. PubMed ID: 31811703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.